Computational systems and methods are described for identifying new α-helical antimicrobial peptides using a systemic consensus formula. Newly identified α-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.

The present invention pertains to a new nanoparticle-like delivery system for intracellular delivery of cargo molecules such as nucleic acids, ribonucleoproteins and extracellular vesicles.

The present invention pertains to a new nanoparticle-like delivery system for intracellular delivery of cargo molecules such as nucleic acids, ribonucleoproteins and extracellular vesicles.

The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods. In some embodiments the addiction is an addiction to smoking, alcohol and/or drugs.

The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods. In some embodiments the addiction is an addiction to smoking, alcohol and/or drugs.

Disclosed herein, in some embodiments, non-naturally occurring proteins (e.g., non-naturally occurring modified proteins) that may be useful in the treatment of bacterial and viral infections, including SARS-CoV-2 infection, host cells comprising the same, and methods of treating bacterial and viral infections including SARS-CoV-2 infection. Also provided herein are host cells comprising fusion proteins for split intein-based selection of peptides that bind a target protein, methods of using the same, and methods of identifying peptides that bind a target protein.

In alternative embodiments, provided are peptides and peptide-comprising compositions, including products of manufacture and kits, and methods, for modulating myosin subfragment-2 coiled coil stability. In alternative embodiments, a peptide modulator of myosin subfragment-2 coiled coil stability as provided herein is administered to an individual in need thereof for: increasing exercise tolerance in a subject with heart failure; reducing hospitalization in a subject with heart failure; improving quality of life in a subject with heart failure; decreasing morbidity in a subject with heart failure; decreasing mortality in a subject with heart failure; modulating skeletal muscle activity for purposes of impacting patient weight; and/or, modulating skeletal muscle activity for purposes of ameliorating consequences of skeletal muscle diseases such as sarcopenia, muscular dystrophies, muscle cramps, and nemaline myopathies.

In alternative embodiments, provided are peptides and peptide-comprising compositions, including products of manufacture and kits, and methods, for modulating myosin subfragment-2 coiled coil stability. In alternative embodiments, a peptide modulator of myosin subfragment-2 coiled coil stability as provided herein is administered to an individual in need thereof for: increasing exercise tolerance in a subject with heart failure; reducing hospitalization in a subject with heart failure; improving quality of life in a subject with heart failure; decreasing morbidity in a subject with heart failure; decreasing mortality in a subject with heart failure; modulating skeletal muscle activity for purposes of impacting patient weight; and/or, modulating skeletal muscle activity for purposes of ameliorating consequences of skeletal muscle diseases such as sarcopenia, muscular dystrophies, muscle cramps, and nemaline myopathies.

The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro).sub.n-His-Pro-His-Ala-Arg-Ile-Lys].sub.m-Y. The peptides are for medical use, in particular as anti-tumoral agents.

The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro).sub.n-His-Pro-His-Ala-Arg-Ile-Lys].sub.m-Y. The peptides are for medical use, in particular as anti-tumoral agents.